Companies /Healthcare

Boston Scientific Corp

NYSE: BSX Medical Devices
$48.30
â–² $1.46 (+3.12%) today
Markets closed · 7:22pm ET

Q4 2025 Earnings

Reported Feb 4, 2026, 6:33am ET · SEC source
$0.80
Beat +2.56%
EPS · est. $0.78
$5.3B
Beat +0.04%
Revenue · est. $5.3B
−3.6%
Trailing market
BSX vs S&P since report
6 quarters
Consecutive EPS beats

Market Reaction

% change · around the report
−18%−12%−6%0Feb 4Feb 5report 6:33am ETearnings−1.3%−15.8%
−18%−12%−6%0Feb 4Feb 5earnings−1.3%−15.8%
BSX −15.8%S&P 500 −1.3%
−18%−12%−6%0Feb 4Feb 5report 6:33am ETearnings−2.4%−15.8%
−18%−12%−6%0Feb 4Feb 5earnings−2.4%−15.8%
BSX −15.8%NASDAQ −2.4%
−7%0+7%+14%Feb 3Feb 12report 6:33am ETearnings+0.4%−10.1%
−7%0+7%+14%Feb 3Feb 12earnings+0.4%−10.1%
BSX −10.1%S&P 500 +0.4%
−7%0+7%+14%Feb 3Feb 12report 6:33am ETearnings−0.3%−10.1%
−7%0+7%+14%Feb 3Feb 12earnings−0.3%−10.1%
BSX −10.1%NASDAQ −0.3%
−17.59%
Day of report
+2.83%
Next session
−2.69%
One week
−4.77%
30 days

S&P 500 over the same 30 days: −1.15%.

Did BSX Beat Earnings? Q4 2025 Results

Boston Scientific closed out 2025 on a strong note, posting Q4 adjusted EPS of $0.80 against a consensus estimate of $0.78, a 2.56% beat, while revenue of $5.29 billion edged past the $5.28 billion estimate and grew 15.9% year over year. The standout driver was the Cardiovascular segment, which expanded 18.2% on a reported basis to $3.48 billion, powered by continued momentum in cardiac ablation and structural heart therapies; the company is also running a clinical trial combining its FARAPULSE and WATCHMAN devices for atrial fibrillation patients, a move that could further entrench its position in cardiac care. Organic growth of 12.7% for the quarter cleared the company's own 11-to-13 percent guidance range, underscoring the breadth of demand across its portfolio. For full year 2025, net sales reached $20.07 billion with adjusted EPS of $3.06. Looking ahead, management guided 2026 reported revenue growth of 10.5 to 11.5 percent and adjusted EPS of $3.43 to $3.49, signaling continued confidence in its diversified medtech platform.

Key Takeaways
  • Cardiovascular segment grew 18.2% reported and 16.1% organic, driving overall growth
  • U.S. region grew 17.0% to $3.385 billion, the strongest regional performer
  • Organic growth of 12.7% exceeded the upper end of company guidance of 11-13%
  • Adjusted EPS of $0.80 exceeded guidance range of $0.77 to $0.79

“2025 was another exceptional year for Boston Scientific, with our global teams delivering differentiated innovation and high performance that enabled us to exceed our goals. As a direct result of the dedication, consistency and winning spirit of our team, we have impacted millions of patient lives and are well-positioned to continue on our strong growth trajectory well into the future.”

Boston Scientific CEO, on the earnings call

Forward Guidance & Outlook

For full year 2026, Boston Scientific estimates net sales growth of approximately 10.5 to 11.5 percent on a reported basis and 10.0 to 11.0 percent on an organic basis versus 2025. Full year 2026 adjusted EPS is expected to be $3.43 to $3.49. For Q1 2026, the company estimates net sales growth of approximately 10.5 to 12.0 percent on a reported basis and 8.5 to 10.0 percent on an organic basis, with adjusted EPS of $0.78 to $0.80.

BSX YoY Financials

Q4 2025 vs Q4 2024 · SEC filings Q4 2024 Q4 2025
$0$2.0B$4.0B$4.6B$5.3BRevenue$2.7B$3.7BGross Profit$589.0M$825.0MOperating Income$566.0M$670.0MNet Income
$0$2.0B$4.0BRevenueGross ProfitOperating IncomeNet Income

BSX Revenue by Segment

Cardiovascular$3.5B+18.2%
Cardiology
MedSurg$1.8B+11.7%
Endoscopy$760.0M+10.1%
Urology$717.0M+13.8%
Peripheral Interventions
Neuromodulation$332.0M+11.1%

BSX Revenue by Geography

United States$3.4B+17.0%
EMEA$933.0M+12.4%
Asia Pacific$788.0M+15.2%
Latin America$179.0M+15.9%

Figures from SEC filings and company reports. Not investment advice.